Hengrui Pharma (01276) rose nearly 4%, gaining 3.76% to HK$23.16 by the time of writing, with a trading volume of HK$50.4121 million.

On October 27, the company released its financial results for the first three quarters of 2025. The group reported revenue of RMB 23.188 billion, up 14.85% year-on-year, and net profit attributable to shareholders of RMB 5.751 billion, a 24.5% increase YoY. Basic earnings per share stood at RMB 0.89.

Additionally, according to an announcement on Hengrui Pharma’s official website, its subsidiary Shandong Sandoz Pharmaceuticals recently received approval from China’s National Medical Products Administration for its self-developed diabetes drug, Henggelieqing Ruigelieting Metformin Extended-Release Tablets (I) and (II) (Ruiletang®). The drug is indicated for improving blood sugar control in adult patients with type 2 diabetes who have inadequate glycemic control with metformin hydrochloride treatment, alongside diet and exercise management.

Notably, Ruiletang® is China’s first domestically developed triple-combination oral antidiabetic drug, marking a significant breakthrough in the country’s diabetes treatment innovation.